



Alnylam Pharmaceuticals, Inc.
Investor Relations Department
300 Third Street
Cambridge, MA 02142
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: ALNY 1

| | |
|-------------------|--------------------------|
| Last Trade: | 81.42 |
| Trade Time: | 4:00 PM ET 08.18.2017 |
| Change: | 1.14 (1.420%) |
| Day Range | 79.79 - 81.99 |
| 52-Week Range | 31.38 - 86.92 |
| Volume | 574,759 |
| Market Cap. (\$M) | 7,468.657 |
| Shares Out (M) | 91.730 |

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics in three strategic therapeutic areas (STAr): genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases. These novel therapeutics carry the potential to transform the lives of patients who have limited or inadequate treatment options. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into a reality, with a robust discovery platform and deep pipeline of investigational medicines, including three product candidates that are i ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 08.09.2017 [Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity](#)
- 08.01.2017 [Alnylam to Webcast Conference Call Discussing Second Quarter 2017 Financial Results](#)
- 07.27.2017 [Alnylam to Host Fourth Annual "RNAi Roundtable" Webcast Series](#)
- 07.10.2017 [Alnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors](#)
- 07.07.2017 [Alnylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors](#)

Events [\[View all \]](#)

- 08.23.2017 3:30 PM ET [2017 RNAi Roundtable: Platform advances in RNAi Therapeutics](#)
- 09.07.2017 10:30 AM ET [2017 RNAi Roundtable: Givosiran, in development for the treatment of acute hepatic porphyrias](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- 02.15.2017 [Annual Report \(10-K\)](#)
- 03.17.2017 [Definitive Proxy Statement](#)
- 08.09.2017 [Quarterly Report \(10-Q\)](#)
- 05.05.2017 [Quarterly Report \(10-Q\)](#)
- 11.03.2016 [Quarterly Report \(10-Q\)](#)